DALLAS, May 13, 2010 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Antigenics Inc. (Nasdaq:AGEN). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
The full report is available at: www.microstockprofit.com/ads/AGEN
Antigenics Inc. (AGEN) is a biotechnology company developing and commercializing technologies to treat cancers and infectious diseases, primarily based on immunological approaches. Oncophage has been tested in Phase III clinical trials for the treatment of renal cell carcinoma, a common type of kidney cancer, and for the treatment of metastatic melanoma. It has also been tested in Phase I and Phase II clinical trials in a range of indications and is in Phase II clinical trials in glioma, a type of brain cancer. Its product candidate portfolio also includes QS-21 Stimulon adjuvant (QS-21), which is used in numerous vaccines in third-party clinical trials as advanced as Phase III for a variety of diseases; AG-707, a therapeutic vaccine program tested in a Phase I clinical trial for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic tested in a Phase I clinical trial for the treatment of solid malignancies and B-cell lymphomas.
Message Board Search for AGEN: http://www.boardcentral.com/boards/AGEN
In the report, the analyst notes:
"The Company reported a net loss attributable to common stockholders of $9.0 million, or $0.10 per share, basic and diluted, for the first quarter of 2010, compared with a net loss attributable to common stockholders in the first quarter of 2009 of $9.7 million, or $0.14 per share, basic and diluted.
"The Company recently announced that Dr. Andrew Parsa of the Brain Tumor Research Center at the University of California, San Francisco (UCSF) will present clinical data from a Phase II trial testing Oncophage in the treatment of recurrent glioma at the International Conference on Brain Tumor Research and Therapy on May 20, 2010."
To read the entire report visit: www.microstockprofit.com/ads/AGEN
See what investors are saying about AGEN at penny stock forum
MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com
MicroStockProfit.com Disclosure
MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.